Steadtrust LLC Boosts Position in InMode Ltd. $INMD

Key Points

• Steadtrust LLC increased its InMode stake by 251.9% in the second quarter, ending with 91,500 shares valued at approximately $1.34 million. Institutional investors collectively own 68.04% of the company.
• InMode reported quarterly EPS of $0.35, matching analyst expectations, while revenue of $95.59 million exceeded estimates of $94.89 million. The company posted a 20.69% net margin and 11.99% return on equity.
• Analyst sentiment remains cautious, with one Buy, six Hold, and one Sell rating; the consensus rating is Hold with an average price target of $16.00, compared with a recent share price of $15.31.

Steadtrust LLC boosted its stake in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 251.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,500 shares of the healthcare company's stock after buying an additional 65,500 shares during the quarter. Steadtrust LLC owned approximately 0.16% of InMode worth $1,338,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Leonteq Securities AG purchased a new position in shares of InMode during the fourth quarter worth approximately $26,000. Quadrant Capital Group LLC raised its stake in shares of InMode by 127.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company's stock valued at $29,000 after acquiring an additional 1,091 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of InMode in the third quarter valued at approximately $37,000. Basepoint Wealth LLC purchased a new stake in shares of InMode in the fourth quarter valued at approximately $39,000. Finally, Deutsche Bank AG grew its stake in InMode by 35.9% in the fourth quarter. Deutsche Bank AG now owns 3,927 shares of the healthcare company's stock worth $58,000 after purchasing an additional 1,037 shares in the last quarter. 68.04% of the stock is owned by hedge funds and other institutional investors.

InMode Price Performance

INMD opened at $15.31 on Monday. The firm has a market capitalization of $880.02 million, a PE ratio of 12.45 and a beta of 1.89. The business's 50-day moving average is $14.52 and its two-hundred day moving average is $14.26. InMode Ltd. has a 1 year low of $12.72 and a 1 year high of $16.74.

InMode (NASDAQ:INMD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The healthcare company reported $0.35 EPS for the quarter, hitting the consensus estimate of $0.35. The firm had revenue of $95.59 million during the quarter, compared to analyst estimates of $94.89 million. InMode had a net margin of 20.69% and a return on equity of 11.99%. InMode's revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.47 EPS.

Analyst Ratings Changes

INMD has been the subject of a number of research analyst reports. Robert W. Baird decreased their target price on InMode from $17.00 to $14.00 and set a "neutral" rating for the company in a research report on Thursday, May 7th. Weiss Ratings reissued a "sell (d+)" rating on shares of InMode in a research report on Thursday. Finally, Barclays set a $19.00 price target on InMode and gave the company an "overweight" rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, InMode presently has an average rating of "Hold" and an average price target of $16.00.

About InMode

InMode Ltd. NASDAQ: INMD is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode's product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source